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Abstract
Background: The membrane-bound cell-surface precursor and soluble forms of heparin-binding
epidermal growth factor-like growth factor (HB-EGF) contribute to many cellular developmental
processes. The widespread occurrence of HB-EGF in cell and tissue types has led to observations
of its role in such cellular and tissue events as tumor formation, cell migration, extracellular matrix
formation, wound healing, and cell adherence. Several studies have reported the involvement of
such extracellular matrix proteins as latent transforming growth factor β -binding protein, TGF-β ,
and fibulin-1 in some of these processes. To determine whether HB-EGF interacts with
extracellular matrix proteins we used the extracellular domain of proHB-EGF in a yeast two-hybrid
system to screen a monkey kidney cDNA library. cDNA clones containing nucleotide sequences
encoding domains of two proteins were obtained and their derived amino acid sequences were
evaluated.
Results: From  3 ×  106 screened monkey cDNA clones, cDNA clones were recovered that
contained nucleotide sequences encoding domains of the monkey latent transforming growth
factor-β  binding protein-3 (MkLTBP-3) and fibulin-1C protein. The amino acid sequence derived
from the MkLTBP-3 gene shared 98.6% identity with human LTBP-3 and 86.7% identity with mouse
LTBP-3 amino acid sequences. The amino acid sequence derived from the monkey fibulin-1C gene
shared 97.2% identity with human fibulin-1C. Yeast two-hybrid screens indicate that LTBP-3 and
fibulin-1C interact with proHB-EGF through their calcium-binding EGF-like modules.
Conclusions: The interactions of the extracellular domain of proHB-EGF with LTBP-3 and fibulin-
1C suggest novel functions for HB-EGF between cell and tissue surfaces.
Background
The precursor of heparin-binding EGF-like growth factor
(proHB-EGF) is found on a wide variety of cell surfaces
and is present in numerous tissue types [1]. Previously in
our laboratory, we cloned the cDNA encoding proHB-EGF
from monkey Vero cells and identified this cell-surface
molecule as a receptor for diphtheria toxin (DT) [2]. The
predicted amino acid sequence was shown to be identical
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to that of the cell surface-expressed precursor of human
heparin-binding EGF-like growth factor (proHB-EGF)
[3,4]. The derived amino acid sequence revealed a signal
sequence (residues 1–23), an extracellular domain (resi-
dues 24–159), a transmembrane domain (residues 160–
184), and a carboxyl terminal cytoplasmic domain (resi-
dues 185–208) [2]. Proteolytic processing of the proHB-
EGF occurs on the cell surface and results in the release of
mature HB-EGF (mHB-EGF) (residues 63–148) [5]. The
mature/soluble HB-EGF is a member of the EGF family of
growth factors that includes amphiregulin, epidermal
growth factor, and transforming growth factor a [6]. Ma-
ture HB-EGF released from the cell surface is mitogenic
and is able to bind to the EGF receptor [3]. Membrane-
bound proHB-EGF has juxtacrine growth factor activity
[7] and also acts as a DT receptor [2,8].
Previously we have described the interaction of the extra-
cellular domain of proHB-EGF with the second extracellu-
lar domain of the tetraspanin protein, monkey CD9 [9].
Tissue culture experiments using DT-sensitive transfected
mouse fibroblast cell lines expressing on the cell surface
both the monkey DT receptor and chimeric mouse-mon-
key CD9 antigen showed that the second extracellular do-
main of monkey CD9 antigen is able to act as a coreceptor
for DT and is also responsible for the increased DT-sensi-
tivity and affinity for DT in these cell lines [9]. These ob-
servations suggested that the CD9 antigen and proHB-
EGF likely interact physically on the cell surface. Using a
yeast two-hybrid system, we have shown that the extracel-
lular domain of proHB-EGF and the second extracellular
domain of monkey CD9 do indeed interact [9].
The yeast two-hybrid system strategy has been used to ex-
amine both intracellular and receptor-ligand protein-pro-
tein interactions. The interaction of mammalian growth
hormone, prolactin, and vascular endothelial growth fac-
tor with their respective extracellular ligand-binding pro-
teins have been observed using yeast two-hybrid sytems
[10–13].
The involvement of HB-EGF in various cellular and tissue
functions and its presence in extracellular matrices sug-
gested the possibility that it may interact with other extra-
cellular matrix proteins. To test this possiblity we used the
extracellular domain of proHB-EGF in a yeast two-hybrid
system to screen a monkey kidney cDNA library. In the
present report, we have identified two novel extracellular
matrix proteins latent transforming growth factor β -bind-
ing protein 3 and fibulin-1C that interact with the extra-
cellular domain of proHB-EGF.
Results and Discussion
Yeast two-hybrid screening of the monkey cDNA library us-
ing the extracellular domain of proHB-EGF as the bait fu-
sion
The initial screening of  3 ×  106 clones of the monkey
cDNA library with the bait fusion of GAL4 binding do-
main fused to the extracellular domain of proHB-EGF
yielded 294 colonies that were able to grow on Trp-His-
Leu- media and that gave positive β -galactosidase activity
in the β -galactosidase filter paper assay. False positives
were ruled out by testing the β -galactosidase activity of the
library clone alone or the library clone and the GAL4 DNA
binding domain plasmid vector together in the yeast host
strain. False positives were also ruled out by testing the β -
galactosidase activity of the library clone with pVA3
(pGBT9 with a cloned insert). The elimination of these
false positive colonies from the initial screening of the
cDNA library resulted in a total of 64 colonies whose li-
brary clones encoded potentially true interacting proteins
with the extracellular domain of proHB-EGF. Some of
these cDNA library clones were transformed into the other
yeast host strain, Y187, and tested for β -galactosidase ac-
tivity as a further check that these clones did indeed con-
tain potential protein-interacting partners for the
extracellular domain of proHB-EGF.
Detection of the physical interactions of proHB-EGF with 
CD9 antigens
The membrane-bound precursor and soluble forms of
heparin-binding epidermal growth factor-like growth fac-
tor (HB-EGF) contribute to a variety of cellular develop-
mental processes [1]. The observations of HB-EGF in cell
and tissue types have suggested roles for HB-EGF in nu-
merous cellular and tissue events such as: cell movement,
extracellular matrix formation, tumor formation and cell
adherence [1]. As described above, the membrane-bound
precursor of HB-EGF (proHB-EGF) is also the cell-surface
receptor for diphtheria toxin (DT) in DT-sensitive cells
[2].
Previously we have examined the protein-protein interac-
tions of proHB-EGF with the cell-surface CD9 antigen [9].
The CD9 antigen is found on a wide variety of tissue and
cell types and has been reported to be involved in such
cellular processes as B-cell development, cell metastasis,
platelet activation and adhesion, and cell motility [14,15].
CD9 antigen is a member of the tetraspanin superfamily
and consists of two extracellular domains sandwiched be-
tween four highly-conserved hydrophobic transmem-
brane domains [14,15]. The second extracellular domain
(75–130 amino acids) is larger than the first extracellular
domain (20–27 amino acids). Short cytoplasmic domains
(5–14 amino acids) are found at both the amino and car-
boxyl termini of CD9 [14]. As reported previously, we
used a yeast two-hybrid system and observed interactionBMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/2
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between the second extracellular domain of MkCD9 and
the extracellular domain of proHB-EGF [9]. However, de-
spite repeated attempts, using the yeast two-hybrid sys-
tem, we were unable to show interaction between the
amino terminal cytoplasmic domain of monkey CD9 and
the cytoplasmic domain of proHB-EGF; these results may
reflect the limitation of the yeast two-hybrid system as the
insert sizes cloned into the vectors may be too small re-
sulting in Gal4 fusion proteins whose "test subunits" are
masked by the Gal4 subunit. This would result in the fu-
sion proteins being unable to recognize each other.
The results of screening the monkey cv-1 cDNA library
with the bait plasmid pGBT9/DTREx were somewhat sur-
prising in that no portions of the CD9 protein were repre-
sented among the proteins found to interact with the
extracellular domain of proHB-EGF. These results may re-
flect improper folding of CD9 protein fragments encoded
by cDNA inserts or these results may be due to under rep-
resentation of the CD9 cDNA in the monkey cv-1 cDNA
library. It was also surprising that the extracellular portion
of any of the EGF receptor proteins was also not represent-
ed among the proteins found to interact with the extracel-
lular domain of proHB-EGF, since the mature protein
proteolytically cleaved from proHB-EGF (mHB-EGF) as
well as the membrane bound form are known to interact
with the EGF receptor.
The extracellular domain of proHB-EGF interacts with 
monkey LTBP-3
The positive interaction of the fragment of the latent
transforming growth factor β -binding protein-3 (LTBP-3)
with the extracellular domain of proHB-EGF was of great
interest (Additional file 1). Recently it has been reported
that treatment of EGF-responsive, nontransformed rat in-
testinal crypt cell line RIE-1 cells with TGF-β  resulted in an
increased level of expression of HB-EGF [16]. LTBP-3 is a
protein that is ubiquitous in tissues and cells. Human
LTBP-3 (Fig. 1) and mouse LTBP-3 contain 1242 and
1251 amino acids, respectively, and each protein has five
structural domains. Each has a signal sequence (55 amino
acids and 49, respectively), a second domain containing
an EGF-like repeat, a proline/glycine rich region, a fibrillin
motif [17], an EGF calcium-binding repeat, and a TGF-β
repeat (390 and 389 amino acids, respectively), a third
domain containing a proline/glycine rich region (113 and
111 amino acids, respectively), a fourth domain contain-
ing numerous calcium-binding type II EGF-like modules
(D/N)(I/V)(D/N)(E/D)C1 (678 and 677 amino acids, re-
spectively) and a fifth carboxyl-terminal domain (5 and
21 amino acids, respectively) (human LTBP-3 informa-
tion was obtained from the GenBank database accession
no. AF135960.2; [18]). Colony hybridization experi-
ments using the LTBP-3 probe (see materials and meth-
ods) and the monkey cv-1 cDNA library yielded a set of six
(two identical) overlapping clones (Fig. 2). The amino
acid sequence derived from the nucleotide sequence ob-
tained for the monkey LTBP-3 sequence (GenBank acces-
sion number AF395658) shows it to share 98.6 % identity
with the human LTBP-3 amino acid sequence (GenBank
accession number NP_066548) and 86.7 % identity with
the mouse LTBP-3 amino acid sequence (GenBank acces-
sion number NP_032546).
The presence of the calcium-binding EGF-like modules in
monkey LTBP-3 is noteworthy. It is well established that
EGF-like modules are important structural features found
in many extracellular proteins and that these modules en-
able numerous protein :protein interactions; the binding
of EGF-like modules in laminin to nidogen [19] and the
interaction of EGF-like modules within fibrillin mono-
mers [20,21]. Calcium may be required for some of these
protein interactions.
At the time of writing, there have not been any reported
interactions of these EGF-like modules in LTBP-3 proteins
with specific proteins. It is interesting that the combina-
Figure 1
Diagrammatic representation of the human LTBP-3 protein.
Note that for the amino acid sequence derived for the mon-
key LTBP-3 (Mk LTBP-3), the monkey, mouse and human
LTBP-3 proteins have the same structural features. Symbols
represent structural features of the protein: cysteine-rich
regions, patterned octagons; proline/glycine rich region, solid
line; fibrillin motif, open rectangle; calcium-binding type II
EGF-like modules, open octagons; cysteine-rich TGF-bp
repeats, dotted punched tape symbol; TGF-bp-like repeat,
wavy lined punched tape symbol. The numbers 1-5 represent
different domains of the protein. The construct insert of
pGAD424/LTBP-3 EGF #1-8, containing the region of Mk
LTBP-3 that interacts with the extracellular domain of
proHB-EGF (DTREx), is shown as a forward slashed box.
5 12 3 4
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tion of colony hybridization and yeast two-hybrid screens
used in this study to identify proteins that interact with
the extracellular domain of proHB-EGF yielded independ-
ent GAL4-LTBP-3 fusion proteins that all contained these
calcium-binding type II EGF-like domains (Fig. 2). A con-
structed clone, pGAD424/LTBP-3 EGF#1-8, that con-
tained calcium-binding type EGF-like modules #1–8
fused to the GAL4-activation domain (see Fig. 1 and ma-
terials and methods) was tested using the yeast two-hy-
brid system and found to interact with the extracellular
domain of proHB-EGF (Additional file 1). These negative-
ly-charged EGF-like modules of LTBP-3 may interact effi-
ciently with the positively-charged heparin-binding
domain of both the membrane-bound and soluble forms
of HB-EGF. The amino acid sequence of the heparin-bind-
ing region of HB-EGF (21KRKKKGKGLGKKRDPCLRKYK41)
[2] has been shown to have a strong affinity for heparin
and may influence the interaction of this growth factor
with cell-surface negatively charged heparan sulfate prote-
oglycans [22]. It remains to be seen whether specific/all of
the EGF-like modules are required and whether calcium is
needed for the interaction of HB-EGF with LTBP-3.
The LTBP-3 protein is secreted as a soluble protein from
the cell surface into the extracellular matrix. Two of the
proposed functions of LTBP proteins include protecting
TGF-β  from premature proteolytic cleavage and targeting
TGF-β  to its appropriate cell-surface receptor. During cel-
lular synthesis of TGF-β , a small latent complex contain-
ing the latency-associated peptide and the mature TGF-β
is synthesized. This small latent complex may be secreted
inefficiently from the cell surface at relatively slow rates
[23]. However, when the small latent complex is bound
by the latent transforming growth factor β -binding pro-
tein via a disulfide bond to the latency-associated peptide,
the result is the formation of a large latent complex which
may be secreted efficiently and at a relatively high rate
compared to the small latent complex [23]. Latent TGF-β
is then released from the extracellular matrix via proteo-
lytic cleavage from the large latent complex, and the re-
sulting active TGF-β  is now able to bind to the appropriate
TGF-β  cell-surface receptors [24].
It is well accepted that TGF-β  is important for the regula-
tion of extracellular matrix synthesis and degradation. The
presence of TGF-β  increases the expression of such extra-
cellular matrix proteins as fibronectin, the fibronectin re-
ceptor, vitronectin, tenascin, elastin, thrombospondin,
collagen, and biglycan [25–32] and also inhibits expres-
sion of proteases that degrade the extracellular matrix
while stimulating the expression of protease inhibitors
[33–36].
It is interesting to note that although Bulus and Barnard
[16] showed that TGF-β  treatment of R1E cells resulted in
increased level of HB-EGF expression, they did not report
any direct physical interactions between the growth fac-
tors TGF-β  and HB-EGF. It may be that LTBP-3 provides a
physical link between soluble mHB-EGF and TGF-β . Pos-
sible functions for the apparent interaction of mHB-EGF
with LTBP-3 include the targeting of the TGF-β  within its
protective large latent complex to its appropriate TGF-β
cell-surface receptor, or the targeting of the TGF-β  large la-
tent complex to the EGF receptor via binding of mHB-EGF
to the appropriate EGF receptor. These are reasonable
functions for the role of the proposed mHB-EGF :LTBP-3
protein:protein interactions as the expression of both
mHB-EGF and TGF-β  is important during extracellular
matrix formation in wound healing [1,25]; it has been
suggested that the coordinated activities of HB-EGF and
TGF-β  regulate the wound healing process [16].
The extracellular domain of proHB-EGF interacts with 
monkey fibulin 1C
The extracellular domain of proHB-EGF interacts with
monkey fibulin-1C (Additional file 1). Fibulin-1 is a cal-
cium-binding extracellular matrix glycoprotein that is as-
sociated with various connective tissues, basement
membranes and blood [37–39]. Splicing of the C terminal
domain of fibulin-1 can lead to the expression of different
variants of fibulin-1 (A-D) [37]. The amino acid sequence
Figure 2
Overlapping monkey cDNA clones containing monkey LTBP-
3 sequence. The numbers displayed next to each clone rep-
resent the nucleotides of the cDNA clone. The numbering
system is based on that presented for the mouse LTBP-3
cDNA sequence in which the A of the intitiator Met codon is
nucleotide 1 (Yin et al. 1995). The fusion proteins encoded
by each of the cDNA clones demonstrated interaction with
the extracellular domain of proHB-EGF when tested for β -
galactosidase activity using the yeast two-hybrid system
assay.
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of the human fibulin-1C protein encodes five domains: a
signal sequence (35 amino acid residues), three anaphyla-
toxin type I repeats (108 residues), an adjoining sequence
(33 amino acid residues), nine calcium-binding type II
EGF-like modules (387 amino acid residues), and a car-
boxyl domain (116 amino acid residues) [37]. The amino
acid sequence derived from the nucleotide sequence ob-
tained for monkey fibulin-1C (GenBank accession
number AF395659) shows it to share 97.2 % identity with
the amino acid sequence for human fibulin-1C (GenBank
accession number NP_001987).
The EGF-like modules found in fibulin-1 are instrumental
in a variety of extracellular protein:protein interactions.
Fibulin-1 has been reported to interact with such extracel-
lular matrix proteins as fibronectin, laminin, nidogen, ag-
grecan and versican [39–42]. Fibronectin is a glycoprotein
found as multimers in insoluble form in the extracellular
matrix. Fibronectin contains three types of homology se-
quences, I-III; type I sequences bind heparin, Staphylococ-
cus aureus, fibrin, and cell surfaces, type II sequences bind
collagen and gelatin, and type III sequences bind DNA,
cell surfaces, heparin, and fibulin-1 [40,43]. Fibulin-1 in-
teracts with fibronectin through a heparin-binding region
in type III13 repeat; the binding of fibulin-1 to this site is
independent of the binding of heparin as addition of ex-
ogenous heparin does not inhibit fibulin-1 binding to fi-
bronectin [40]. The fibronectin-binding site in fibulin-1 is
located in EGF-like modules 5 and 6 [44]; the binding of
fibulin-1 to fibronectin is a heterotypic interaction in
which an EGF-like module binds to a non EGF-like do-
main (the type III13 fibronectin repeat) [40].
Laminin is a glycoprotein composed of three chains, A,
B1, and B2 in a cross-shaped molecule; this protein is
found in basement membranes where it interacts with
other such components as collagen IV, heparan-sulfate
proteoglycan, and nidogen [45]. Laminin contains EGF-
like modules in the amino-terminal region of the A, B1,
and B2 chains [45]. Surprisingly, these modules do not
appear to be involved in the binding of fibulin-1. The site
of fibulin-1 binding to laminin maps to the carboxyl-ter-
minal segment of the laminin A chain which consists of
five basic tandem repeats containing conserved glycine
and cysteine residues [39,46]. The binding site of laminin
to fibulin-1 maps to the calcium-binding type II EGF-like
modules of fibulin-1 [39].
Nidogen is a basement membrane protein composed of
three globular domains G1-G3 and two linking sequenc-
es; domain G1 is joined to domain G2 through a flexible
link and domain G2 is connected to domain G3 by a rod-
like element consisting of EGF-like modules [47].
Nidogen1 is an important structural component of terti-
ary complexes with other such extracellular components
as laminins, collagen IV, perlecan, and fibulins [48]. Fibu-
lin-1C binds to nidogen1 through domain G2 of nidogen
[48]. The nidogen binding site of fibulin-1C includes the
type II EGF-like modules 6–9 and the carboxyl-terminal
domain [42].
Aggrecan and versican are aggregating proteoglycans that
are key constituents found in the extracellular matrix [41].
Both proteoglycans contain amino-terminal hyaluronic
acid-binding regions, central core glycosaminoglycan at-
tachment domains, and carboxyl-terminal domains con-
taining EGF-like modules (one in aggrecan and two in
versican), C-type lectin like modules and complement
regulatory protein-like modules [49,50]. Fibulin-1 exhib-
its calcium-dependent binding to the carboxyl-terminal
domain of aggrecan and versican [41]. The binding site of
aggrecan to fibulin-1 maps to the type II EGF-like modules
8–9 and the carboxyl-terminal domain of fibulin-1 [41].
The binding site of versican to fibulin-1 maps to the type
II EGF-like modules 2–8 of fibulin-1 [41].
Fibulin-1 has been reported two exhibit calcium-depend-
ent self-association [40,44]. The two self-association sites
map to type II EGF-like modules 5 and 6 and to a cryptic
site in the amino-terminal region of fibulin-1 [40,44].
As described above, the calcium-binding type II EGF-like
modules of fibulin-1 are used in various extracellular ma-
trix interactions. It is noteworthy that these modules may
interact with other EGF-like modules or with non EGF-
like modules.
The yeast two-hybrid system and colony hybridization
screens used in this study indicated that a monkey cDNA
clone (Fig. 3), containing half of the anaphylatoxin type I
repeats, an EGF-adjoining sequence, calcium-binding
EGF-like modules and a carboxyl-terminal fibulin-type
module, demonstrated interaction with the extracellular
domain of proHB-EGF (Additional file 1). To see if the
any/all of the calcium-binding EGF-like modules were
necessary for this interaction, two clones were construct-
ed. A clone, pGAD424/Fib-1C EGF #5-COOH, that con-
tained calcium-binding type EGF-like modules #5–9 and
the carboxyl-terminus of fibulin-1C fused to the GAL4-ac-
tivation domain (see Fig. 3 and materials and methods)
was tested using the yeast two-hybrid system and found to
interact with the extracellular domain of proHB-EGF (Ta-
ble 1). In constrast, the construct, pGAD424/Fib-1C
EGF#1-5, that contained calcium-binding type II EGF-like
modules #1–5 fused to the GAL4 activation domain (see
Fig. 3 and materials and methods) did not interact with
proHB-EGF (Additional file 1). It remains to be deter-
mined which of the regions within the EGF-like modules
#5–9 (e.g. hydroxylation and glycosylation sites) and the
carboxyl-terminus of fibulin-1C are necessary for the in-BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/2
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teraction with proHB-EGF. The interaction of fibulin-1C
may map to the heparin-binding region of the extracellu-
lar domain of proHB-EGF or it may map to the EGF-like
module of proHB-EGF or it may map to both of these re-
gions within proHB-EGF. To test whether the fibulin-1C
interaction with proHB-EGF maps to the heparin-binding
region, a construct, pGBT9/prodelHB-EGF, containing
amino acid residues Asp106-His159 (the entire EGF like re-
gion of proHB-EGF and 18 out of 32 residues of the
heparin-binding region) [2] was used in the yeast two-hy-
brid system (see materials and methods). Construct
pGBT9/prodelHB-EGF was unable to interact with
pGAD424/Fib-1C EGF#5-COOH (data not shown). Cau-
tion must be used with this result however, as the size of
the cloned prodelHB-EGF region is small, encoding just
54 amino acids; this may have resulted in a Gal4 fusion
protein in which the EGF epitopes in prodelHB-EGF are
hidden by the Gal4 subunit and thus not recognized by
the GAL4 fusion partner protein (GAL4/Fib-lC EGF #5-
COOH).
Fibulin-1 is incorporated into fibronectin-containing ma-
trix fibers [44,51]. Although a distinct function for fibulin-
1 has not yet been described, it is conceivable that fibulin-
1 is important for cell adhesion and migration along pro-
tein fibers within the extracellular matrix. Fibulin-1 may
serve to anchor the mHB-EGF to its fibers as it migrates
through the extracellular matrix. As explained above,
mHB-EGF has been reported to be involved as a structural
protein in such tissue developmental processes as wound
healing and it is feasible that the direct physical associa-
tion of mHB-EGF with fibulin-1 may be useful in the tis-
sue remodeling of a wound site and in scar formation.
The results presented in this paper now suggest that there
is potential in carrying out experiments to further deline-
ate the molecular interactions between proHB-EGF and
LTBP-3 and between proHB-EGF and fibulin-1C. A transi-
tional step in this process will be the expression and puri-
fication of these proteins. In order to rule out false
positives that may have resulted from the yeast two-hy-
brid system, experiments that provide co-immunoprecip-
itation data or solid phase binding results of the
interaction of these proteins will be useful.
The interaction of EGF-modules with either non EGF-like
modules (e.g. the EGF-like modules of fibulin-1C interact-
ing with the heparin-binding region of fibronectin) or
with EGF-like modules (e.g. the interaction of fibulin-1C
with aggrecan and versican) between extracellular matrix
proteins argues for the interaction of the EGF-modules
containing within fibulin-1C and LTBP-3 with either the
heparin-binding region or with the EGF-like domain of
HB-EGF.
Conclusions
In summary, we have shown the interaction of two novel
proteins with the extracellular domain of proHB-EGF us-
ing a yeast two-hybrid system. The interactions of LTBP-3
and fibulin-1C with the extracellular domain of proHB-
EGF may provide further insights into the roles that these
proteins play in cellular and tissue development process-
es. The trafficking of such growth factors as HB-EGF and
TGF-β  and structural proteins within the extracellular ma-
trix is important in wound healing processes. Therefore,
the interactions of HB-EGF with LTBP-3 and fibulin-1C
described in this study suggest novel functions for HB-
EGF between cell-surfaces and tissue surfaces.
Materials and methods
The plasmid vectors, pGBT9, pGAD424, pTD1, pVA3, the
monkey cv-1 cDNA library in pGAD10, and the S. cerevi-
siae strains Y187 and Y190 were obtained from Clontech.
The cv-1 cDNA library was amplified and stored as per the
manufacturer's instructions. Unless otherwise noted, all
chemicals and reagents were obtained from Sigma.
Figure 3
Diagrammatic representation of the human fibulin-1C pro-
tein (modified after Argraves et al. [33]). Note that for the
derived amino acid sequence obtained for the monkey fibu-
lin-1C protein, the human and monkey fibulin-1C proteins
have identical structural features. Symbols represent the fol-
lowing structural features: anaphylatoxin type I repeats, dia-
monds; potential N-glycosylation site, small circle; EGF-
adjoining sequence, dotted oval; calcium-binding type II EGF-
like modules, open octagons; potential Asn/Asp hydroxyla-
tion site, triangles, potential o-glycosylation site, inverted tri-
angles; fibulin-type module, large hexagon. The construct
insert of pGAD424/Fib-1C EGF #1–5 is represented by a
dotted box. The construct insert of pGAD424/Fib-1C EGF
#5-COOH, containing a region of fibulin-1C that interacts
with the extracellular domain of monkey proHB-EGF
(DTREx), is represented by a forward slashed box.
COOH
DTREx binding region
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E. coli strain DH5α  was used as the host strain for cloning.
The extracellular domain (amino acid residues Glu24-
His159) of monkey proHB-EGF (GenBank accession
number Q09118) [2] was amplified by PCR using primers
MkHB-EGFex(5') TCGGCACTGGTGGAATTCGAGAGCCT-
GGAG and MKHB-EGFex(3') CACAGCCAGGATGGATC-
CATGGTCATAGGT. The PCR product was digested with
EcoRI and BamHI and ligated into the EcoRI and BamHI re-
striction sites of pGBT9 and pGAD424 to produce con-
structs pGBT9/proHB-EGFEx and pGAD424/proHB-
EGFEx, respectively. The pGBT9/proHB-EGFEx construct
was used as the bait construct in the yeast two-hybrid
screen to identify extracellular proteins that interact with
the extracellular domain of proHB-EGF. The EGF-like re-
gion (amino acid residues Asp106-His159) of monkey pro-
HB-EGF [2] was amplified by PCR using primers MkHB-
EGF 5'CTAGGGAAGGAATTCGACCCATGTCTTCGG and
MkHB-EGF 3'CACAGCCAGGATGGATCCTCAATGGT-
CATAGG. The PCR product was digested with EcoRI and
BamHI and ligated into the EcoRI and BamHI restriction
sites of pGBT9 to produce construct pGBT9/prodelHB-
EGF.
All plasmid constructs were transformed into the S. cerevi-
siae strains, Y187 and Y190, using the lithium acetate pro-
tocol as per the manufacturer's instructions. Y190
transformants containing pGBT9/proHB-EGFEx and
pGAD10/cv-1 library were plated onto Trp-Leu-His- agar
plates. The triple auxotrophic transformants were tested
for β -galactosidase activity using the filter paper assay de-
scribed in the manual provided by Clontech. A positive
control of Y187 or Y190 containing both plasmids pTD1
and pVA3 together was included in every β -galactosidase
assay. A negative control of Y187 or Y190 containing both
plasmid vectors, pGBT9 and pGAD424, was included in
all β -galactosidase assays.
Each construct from the cDNA library that tested positive
for both lacZ and his reporter gene expression was also
tested for the ability to activate directly β -galactosidase/his
reporter gene transcription without the presence of the
bait construct, pGBT9/proHB-EGFEx. False positives were
eliminated using this screening assay. Potential true posi-
tive clones were sequenced using primers GAD10SEQ
5'TACCACTACAATGGATG and GAD10cSEQ 5'GTT-
GAAGTGAACTTGCGGGG with the automated DNA se-
quencing facilities available at our Institution.
Comparisons of the obtained sequences were made using
the GENBANK database. The sequences for monkey LTBP-
3 and monkey fibulin-1c have been submitted to the Gen-
Bank database under the accession numbers AF395658
and AF395659 respectively. Sequence alignment and
identity was determined using the Mac Vector sequence
analysis program.
The calcium-binding type II EGF-like modules #1–8 of
monkey LTBP-3 (Fig. 1) were amplified by PCR using
primers GAD10SEQ 5'TACCACTACAATGGATG and
LB3priLQGSYVC 5'CGCGGATCCTCAACACACATAG-
GAGCCCTGAAG. The PCR product was digested with
EcoRI and BamHI and ligated into the EcoRI and BamHI re-
striction sites of pGADA424 to produce construct
pGAD424/LTBP-3 EGF#1–8. The construct was se-
quenced as described above using the primers
pGAD10SEQ and pGAD10cSEQ.
The calcium-binding type II EGF-like modules #1–5 (Fig.
3) of monkey fibulin-1C were amplified by PCR using
primers Fib5priYLNDRC 5'CGAATTCTATCTGAATGAC-
CGCTGC and Fib3priCAPPAE 5'CCGTCGACTCACTCAG-
CAGGTGGCGCGCA. The calcium-binding type II EGF-
like repeats #5–9 (Fig. 3) and the carboxyl terminus of
monkey fibulin-1C were amplified by PCR using primers
Fib5priCAPPAE 5'CGAATTCTGCGCGCCACCTGCTGA
and Fib3priFVSAEL 5'CCGTCGACTCAGAGCTCTGCA-
GACACAAA. The PCR products were digested with EcoRI
and SalI and ligated into the EcoRI and SalI restriction sites
of pGAD424 to produce constructs pGAD424/Fib-1C
EGF#1-5 and pGAD424/Fib-1C EGF#5-COOH respec-
tively. The constructs were sequenced as described above
using primers pGAD10SEQ and pGAD10cSEQ.
A random primed P33 labeled 1.8 kb DNA probe to the re-
gion of LTBP-3 gene containing domain 4 was prepared
using the High Prime Labeling Kit from Roche Molecular
Biochemicals. Colony hybridizations were performed on
E. coli colonies containing the monkey cv-1 cDNA library.
Colony lifts on zeta probe membranes (Bio-Rad) were
performed and the colonies were denatured and neutral-
ized as described by Sambrook et al. [52] air dried and
then UV cross-linked using a Stratagene crosslinker. The
probe was allowed to hybridize to the colony DNA at
42°C overnight as described by Sambrook et al. [52]. The
membranes were then rinsed and washed twice for 5 min-
utes in 2X SSC/0.1% SDS at room temperature, twice for
15 minutes in 0.1X SSC/0.1 % SDS at 68°C, and once for
15 minutes in 0.1X SSC/0.1% SDS at room temperature.
The colony blots were then wrapped in saran wrap and ex-
posed to X-ray film at room temperature for 24 h at -80°C.
The above strategy was used to perform colony blot hy-
bridization screening on the monkey cv-1 cDNA library
using a ~750 bp P33-labeled probe to a region of the fibu-
lin-1C gene containing most of the type I anaphylatoxin
repeats and almost all of the type II EGF-like repeats (Fig.
3).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/2
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